按年龄、分期和受体亚型划分的青少年和年轻成人乳腺癌患者诊断后5年至10年的条件相对生存率

IF 7.6 Q1 ONCOLOGY
Noëlle J.M.C. Vrancken Peeters , Daniël J. van der Meer , Marleen Kok , Marissa C. van Maaren , Marie-Jeanne T.F.D. Vrancken Peeters , Sabine Siesling , Winette T.A. van der Graaf , Olga Husson
{"title":"按年龄、分期和受体亚型划分的青少年和年轻成人乳腺癌患者诊断后5年至10年的条件相对生存率","authors":"Noëlle J.M.C. Vrancken Peeters ,&nbsp;Daniël J. van der Meer ,&nbsp;Marleen Kok ,&nbsp;Marissa C. van Maaren ,&nbsp;Marie-Jeanne T.F.D. Vrancken Peeters ,&nbsp;Sabine Siesling ,&nbsp;Winette T.A. van der Graaf ,&nbsp;Olga Husson","doi":"10.1016/j.jncc.2025.01.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Conditional relative survival (CRS), the probability of survival given that an individual has already survived a certain period post-diagnosis, is a more clinically relevant measure for long-term survival than standard relative survival (RS). This study aims to evaluate the 5-year CRS among adolescent and young adult (AYA) breast cancer patients by age, tumor stage, and receptor subtype to guide disclosure periods for insurance.</div></div><div><h3>Methods</h3><div>Data of all females aged 18–39 years and diagnosed with invasive breast cancer between 2003 and 2021 (<em>n</em> = 13,075) were obtained from The Netherlands Cancer Registry (NCR). The five-year CRS was calculated annually up to 10 years post-diagnosis using a hybrid analysis approach.</div></div><div><h3>Results</h3><div>For the total AYA breast cancer study population the 5-year CRS exceeded 90 % from diagnosis and increased beyond 95 % 7 years post-diagnosis. Patients aged 18–24 reached 95 % 9 years post-diagnosis, those aged 25–29 after 5 years, and those aged 30–34 and 35–39 after 8 years. For stage I, the 5-year CRS reached 95 % from diagnosis, for stage II after 6 years, while the 5-year CRS for stages III and IV did not reach the 95 % threshold during the 10-year follow-up. Triple-negative tumors exceeded 95 % after 4 years, human epidermal growth factor receptor 2 (HER2) positive tumors after 6 years, while hormone receptor (HR) positive tumors did not reach 95 %.</div></div><div><h3>Conclusion</h3><div>Excess mortality among AYA breast cancer patients tends to be little (CRS 90 %–95 %) from diagnosis and becomes minimal (CRS&gt;95 %) over time compared to the general population. These results can enhance expectation management and inform policymakers, suggesting a shorter disclosure period.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"5 3","pages":"Pages 297-305"},"PeriodicalIF":7.6000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtype\",\"authors\":\"Noëlle J.M.C. Vrancken Peeters ,&nbsp;Daniël J. van der Meer ,&nbsp;Marleen Kok ,&nbsp;Marissa C. van Maaren ,&nbsp;Marie-Jeanne T.F.D. Vrancken Peeters ,&nbsp;Sabine Siesling ,&nbsp;Winette T.A. van der Graaf ,&nbsp;Olga Husson\",\"doi\":\"10.1016/j.jncc.2025.01.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Conditional relative survival (CRS), the probability of survival given that an individual has already survived a certain period post-diagnosis, is a more clinically relevant measure for long-term survival than standard relative survival (RS). This study aims to evaluate the 5-year CRS among adolescent and young adult (AYA) breast cancer patients by age, tumor stage, and receptor subtype to guide disclosure periods for insurance.</div></div><div><h3>Methods</h3><div>Data of all females aged 18–39 years and diagnosed with invasive breast cancer between 2003 and 2021 (<em>n</em> = 13,075) were obtained from The Netherlands Cancer Registry (NCR). The five-year CRS was calculated annually up to 10 years post-diagnosis using a hybrid analysis approach.</div></div><div><h3>Results</h3><div>For the total AYA breast cancer study population the 5-year CRS exceeded 90 % from diagnosis and increased beyond 95 % 7 years post-diagnosis. Patients aged 18–24 reached 95 % 9 years post-diagnosis, those aged 25–29 after 5 years, and those aged 30–34 and 35–39 after 8 years. For stage I, the 5-year CRS reached 95 % from diagnosis, for stage II after 6 years, while the 5-year CRS for stages III and IV did not reach the 95 % threshold during the 10-year follow-up. Triple-negative tumors exceeded 95 % after 4 years, human epidermal growth factor receptor 2 (HER2) positive tumors after 6 years, while hormone receptor (HR) positive tumors did not reach 95 %.</div></div><div><h3>Conclusion</h3><div>Excess mortality among AYA breast cancer patients tends to be little (CRS 90 %–95 %) from diagnosis and becomes minimal (CRS&gt;95 %) over time compared to the general population. These results can enhance expectation management and inform policymakers, suggesting a shorter disclosure period.</div></div>\",\"PeriodicalId\":73987,\"journal\":{\"name\":\"Journal of the National Cancer Center\",\"volume\":\"5 3\",\"pages\":\"Pages 297-305\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the National Cancer Center\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667005425000407\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Center","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667005425000407","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

条件相对生存(CRS)是指患者在诊断后已经存活一段时间的生存概率,与标准相对生存(RS)相比,它是一种与临床更相关的长期生存指标。本研究旨在通过年龄、肿瘤分期和受体亚型评估青少年和青壮年乳腺癌患者的5年CRS,以指导保险披露期。方法从荷兰癌症登记处(NCR)获得2003年至2021年间年龄在18-39岁并诊断为浸润性乳腺癌的所有女性(n = 13075)的数据。使用混合分析方法每年计算5年CRS,直至诊断后10年。结果在所有AYA乳腺癌研究人群中,诊断后5年CRS超过90%,诊断后7年CRS超过95%。18-24岁患者确诊后9年95%,25-29岁患者确诊后5年95%,30-34岁和35-39岁患者确诊后8年95%。对于I期患者,诊断后5年CRS达到95%,对于II期患者,6年后达到95%,而III期和IV期患者的5年CRS在10年随访期间未达到95%的阈值。三阴性肿瘤4年后超过95%,人表皮生长因子受体2 (HER2)阳性肿瘤6年后超过95%,而激素受体(HR)阳性肿瘤未达到95%。结论与普通人群相比,AYA乳腺癌患者的超额死亡率从诊断开始就很少(CRS为90% - 95%),随着时间的推移逐渐降低(CRS> 95%)。这些结果可以加强期望管理并为决策者提供信息,建议缩短披露周期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtype

Background

Conditional relative survival (CRS), the probability of survival given that an individual has already survived a certain period post-diagnosis, is a more clinically relevant measure for long-term survival than standard relative survival (RS). This study aims to evaluate the 5-year CRS among adolescent and young adult (AYA) breast cancer patients by age, tumor stage, and receptor subtype to guide disclosure periods for insurance.

Methods

Data of all females aged 18–39 years and diagnosed with invasive breast cancer between 2003 and 2021 (n = 13,075) were obtained from The Netherlands Cancer Registry (NCR). The five-year CRS was calculated annually up to 10 years post-diagnosis using a hybrid analysis approach.

Results

For the total AYA breast cancer study population the 5-year CRS exceeded 90 % from diagnosis and increased beyond 95 % 7 years post-diagnosis. Patients aged 18–24 reached 95 % 9 years post-diagnosis, those aged 25–29 after 5 years, and those aged 30–34 and 35–39 after 8 years. For stage I, the 5-year CRS reached 95 % from diagnosis, for stage II after 6 years, while the 5-year CRS for stages III and IV did not reach the 95 % threshold during the 10-year follow-up. Triple-negative tumors exceeded 95 % after 4 years, human epidermal growth factor receptor 2 (HER2) positive tumors after 6 years, while hormone receptor (HR) positive tumors did not reach 95 %.

Conclusion

Excess mortality among AYA breast cancer patients tends to be little (CRS 90 %–95 %) from diagnosis and becomes minimal (CRS>95 %) over time compared to the general population. These results can enhance expectation management and inform policymakers, suggesting a shorter disclosure period.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
14.20
自引率
0.00%
发文量
0
审稿时长
70 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信